Raymond James downgraded Omega Therapeutics (OMGA) to Market Perform from Outperform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OMGA:
- Omega Therapeutics price target lowered to $4 from $9 at Piper Sandler
- Omega Therapeutics provides updated MYCHELANGELO I data
- Omega Therapeutics CEO Mahesh Karande to depart, Kaan Certel to succeed
- Omega Therapeutics reports Q3 revenue $2.61M, consensus $1.34M
- Omega Therapeutics Restructures Leadership and Strategic Focus
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
